<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01079312</url>
  </required_header>
  <id_info>
    <org_study_id>a001c</org_study_id>
    <secondary_id>2008-007968-42</secondary_id>
    <nct_id>NCT01079312</nct_id>
  </id_info>
  <brief_title>Patient-controlled Sedation With Propofol and Remifentanyl for Endoscopic Retrograde Cholangiopancreatography (ERCP)</brief_title>
  <official_title>Patient-controlled Sedation vs Propofol Infusion for ERCP:a Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Deep sedation with propofol and opioid is commonly used for endoscopic retrograde
      cholangiopancreatography (ERCP), but is associated with increased morbidity and mortality.
      Delivery of propofol and short-acting potent opioid analgesic using a self-administration
      device (patient-controlled sedation, PCS) could be another option for this purpose.
      Comparative studies with PCS for ERCP are lacking.The main objective of this prospective
      randomized trial trial was to compare PCS with propofol/remifentanil to anaesthesiologist
      managed propofol sedation during ERCP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      80 elective ERCP patients were randomized to anaesthesiologist managed propofol sedation
      (PI-group) or PCS with propofol/remifentanil (PCS-group). Sedation degree was estimated every
      5 min throughout the procedure using Ramsay´s and Gillham´s sedation scores. Total amount of
      propofol was calculated at the end of procedure. Endoscopists´ and patients´ satisfaction was
      evaluated with questionary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>propofol and opioid consumption</measure>
    <time_frame>one day</time_frame>
    <description>total consumption of propofol,milligramms and opioid,microgramms during ERCP procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>vital signs</measure>
    <time_frame>one day</time_frame>
    <description>heart rate,blood pressure,peripheral oxygen saturatuion,breathing rate,expiratory carbon dioxide concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>patient´s and endoscopist´s satisfaction</measure>
    <time_frame>one day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>sedation level</measure>
    <time_frame>one day</time_frame>
    <description>sedation level assested with Ramsay,Gillham,OAA/S sedation scores</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Endoscopic Retrograde Cholangiopancreatography</condition>
  <arm_group>
    <arm_group_label>Propofol infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anaesthesiologist`s managed intravenous infusion of propofol 10mg/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient-controlled sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>self-administration of propofol and remifentanil mixture during ERCP</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>infusion pump</intervention_name>
    <description>anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level</description>
    <arm_group_label>Propofol infusion</arm_group_label>
    <other_name>-Braun AG</other_name>
    <other_name>-an infusion pump</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>infusion pump for patient-controlled sedation</intervention_name>
    <description>self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.</description>
    <arm_group_label>Patient-controlled sedation</arm_group_label>
    <other_name>-Arcomed,Syramed AG,Switzerland</other_name>
    <other_name>-infusion pump designed for self administration of the drugs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol</intervention_name>
    <description>Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.</description>
    <arm_group_label>Propofol infusion</arm_group_label>
    <arm_group_label>Patient-controlled sedation</arm_group_label>
    <other_name>-Diprivan</other_name>
    <other_name>-Recofol</other_name>
    <other_name>-Fresofol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fentanyl</intervention_name>
    <description>Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.</description>
    <arm_group_label>Propofol infusion</arm_group_label>
    <other_name>-fentanyl citrate</other_name>
    <other_name>-fentanyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sedative mixture</intervention_name>
    <description>Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)</description>
    <arm_group_label>Patient-controlled sedation</arm_group_label>
    <other_name>-Ultiva</other_name>
    <other_name>-Diprivan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil hydrochlorid</intervention_name>
    <description>Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)</description>
    <arm_group_label>Patient-controlled sedation</arm_group_label>
    <other_name>-Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  elective ERCP-patients

        Exclusion Criteria:

          -  allergy to propofol or opioid;

          -  ASA-class (American Society of Anaesthesiology) greater than 3;

          -  inability to co-operate;

          -  drugs abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxim Mazanikov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Anaesthesiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Udd, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Outi Lindström, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leena Kylänpää, Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pekka Aho, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Vascular Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorma Halttunen, Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martti Färkilä, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Gasroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reino Pöyhiä, Docent</last_name>
    <role>Study Chair</role>
    <affiliation>Helsinki University Central Hospital,Department of Anaesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital,Meilahti hospital,Endoscopy unit</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2010</study_first_posted>
  <last_update_submitted>July 4, 2012</last_update_submitted>
  <last_update_submitted_qc>July 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Maxim Mazanikov</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>patient-controlled sedation</keyword>
  <keyword>propofol</keyword>
  <keyword>remifentanil</keyword>
  <keyword>sedation level</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
    <mesh_term>Hypnotics and Sedatives</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

